ArticleInvestigational new drugs2014

In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).

Aya Kikuchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.